Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: An orodispersible solid pharmaceutical dosage unit of estetrol is disclosed. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration. The orodispersible solid pharmaceutical dosage unit can include at least 100 ?g of an estetrol component and pharmaceutically acceptable excipients. Methods of manufacturing the orodispersible solid pharmaceutical dosage unit are also disclosed.

Abstract: The invention relates to a binder polymer obtainable by copolymerizing a monomer mixture comprising a vinyl monomer M1 and a butenolide monomer M2, wherein the vinyl monomer M1 is a vinyl ether, a vinyl ester, or a combination thereof, and wherein the butenolide monomer M2 is a 5-alkoxy-2(5H)-furanone. The invention further relates to a coating composition comprising such binder polymer and to a substrate coated with a coating deposited from such coating composition.

Abstract: A system configured to generate a motion adjustment instruction for a user performing an action is provided. The system comprises: a target module configured to obtain a target biomechanical load distribution for the user, a sensor arrangement configured to monitor the motion of the user so as to obtain monitored motion data, a monitoring module configured to calculate a monitored biomechanical load distribution for the user in accordance with the monitored motion data, an adjustment module configured to calculate a target adjustment to the motion of the user that corresponds to a reduction of a deviation of the monitored biomechanical load distribution from the target biomechanical load distribution, and an instruction module configured to generate a motion adjustment instruction in accordance with the target adjustment.

Abstract: The invention relates to a method, to a device, and to a computer-readable storage medium with instructions for monitoring the movement of a transportation device. In one embodiment, first, information about the trajectory of the transportation device is received by a mobile device. The trajectory is then displayed on a display unit of the mobile device in the form of an augmented reality representation. In response thereto, an input of the user of the mobile device for influencing the trajectory is detected. Finally, information is transmitted to the transportation device on the basis of the input of the user.

Abstract: The invention is directed to a pigment transfer sheet (1) suitable for transferring an image to a textile substrate (2), said transfer sheet comprising a base layer and a transfer layer, said transfer layer being present in an amount of 5 to 20 g/m2, preferably in an amount of 8 to 15 g/m2 such as about 12 g/m2. A further aspect of the present invention is a process wherein this transfer sheet is used for transferring an image from a pigment transfer sheet to a textile substrate to provide a textile product carrying said image, said process comprising a transfer step comprising applying a surface pressure of at least 0.4 bar and heat to the superimposed contacted transfer sheet and textile substrate. Yet another aspect of the invention is a textile product (3) obtainable by the sheet and the process, which textile product has favorable properties like good hand and color fastnesses.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt.% of estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt.% of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 µg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 µm to 50 µm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: The present invention relates to a method and system for determining a central pulse wave velocity in a pregnant woman. The method comprises receiving an indication of a measurement of a length of a human aortic path outside the body to provide an aortic length, arranging a sound transducer at the position of the anatomical projection of the uterine artery, identifying the opening of the maternal aortic valve with measurement from the sound transducer as a first time, and the pulse wave arrival time at the uterine artery with measurements from the sound transducer as a second time, determining the central transit time based on the difference between the second time and the first time, and calculating the central pulse wave velocity based on the aortic length and the central transit time.

Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.

Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.

Abstract: The invention provides a system for monitoring a fetus in a pregnant woman, and/or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders. The system comprises a portable or wearable unit that can be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. in the form of an adhesive patch. The portable unit has a sound sensor, e.g. a microphone or accelerometer, to be positioned on the skin of the abdominal area of the pregnant woman so as to detect a vascular sound from umbilical arteries of the fetus or from the uterine arteries of the pregnant woman. The sound sensor is functionally connected to a processing unit which executes a processing algorithm on the captured vascular sound and extracts a signal parameter accordingly, e.g. the Pulsatility Index. The processing unit then communicates the signal parameter, e.g. using an audio signal, a visual display or by means of a wired or a wireless data signal.

Abstract: A method for assessment and/or monitoring a person's cardiovascular state comprises: using a sound and vibration transducer to acquire a vascular sound signal in order to detect a vascular sound from a cervical, thoracic, abdominal, pelvic, or lower limb region of the person; filtering the vascular sound signal to isolate the vascular sound, said filtering using a filter which attenuates frequencies below a lower cut-off frequency in a range of 100-300 Hz; and analyzing the filtered sound signal in order to determine whether an indication of a dicrotic notch in the vascular sound exceeds a set threshold.

Abstract: The present invention relates to tablet dosage formulations of oleyl phosphocholine for oral administration and the processes for their preparation. Specifically, the present invention provides a process for preparing an oleyl phosphocholine containing granulate, said process comprising a blending step, a hot melt agglomeration step and a milling step. The present invention further provides a process for preparing a tablet comprising the oleyl phosphocholine containing granulate, said process comprising the step of preparing an OIPC containing granulate according to the invention, a blending step, a compression step, and optionally a coating step. The invention further provides any intermediate and/or en product resulting from these steps and processes.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: A system for monitoring a fetus in a pregnant woman, and/or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders is configured to be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. in the form of an adhesive patch. The unit has a sound sensor, e.g. a microphone or accelerometer, to be positioned on the skin of the abdominal area so as to detect a vascular sound from umbilical arteries of the fetus or from the uterine arteries of the pregnant woman. The sound sensor is functionally connected to a processing unit which executes a processing algorithm on the captured vascular sound and extracts a signal parameter accordingly. The processing unit then communicates the signal parameter, e.g. using an audio signal, a visual display or by means of a wired or a wireless data signal.

Abstract: A method for analyzing a condition of a heart, comprises receiving a plurality of electric signals, which are acquired by non-invasive measurement on the skin of a person or animal, each signal representing electrical activity in a respective region of the heart of the person or animal; calculating a derivative value of each signal at a plurality of time instances; selecting a plurality of the calculated derivative values of a first signal and determining a first point in time of a first event based on the selected derivative values; selecting a plurality of the calculated derivative values of a second signal and determining a second point in time of a second event, corresponding to the first event, based on the selected derivative values of the second signal, and calculating at least one measure based on a difference of the first point in time and the second point in time.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process that comprises: providing a loading liquid comprising organic solvent; estetrol component and optionally one or more other pharmaceutically acceptable ingredients; mixing 1 part by weight of the loading liquid with 0.5-20 parts by weight of carrier particles to produce wet particles; removing organic solvent from the wet particles to produce loaded particles; optionally mixing the loaded particles with one or more tabletting excipients; and forming the loaded particles or the mixture of the loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.